Center-Authored Papers

Filters: Author is Robertson, Michael N  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
2008
Priddy FH, Brown D, Kublin J, Monahan K, Wright DP, Lalezari J, Santiago S, Marmor M, Lally M, Novak RM et al..  2008.  Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults.. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 46(11):1769-81. Abstract
Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, Gilbert PB, Lama JR, Marmor M, del Rio C et al..  2008.  Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial.. Lancet. 372(9653):1881-93. Abstract
McElrath MJ, De Rosa SC, Moodie Z, Dubey S, Kierstead L, Janes H, Defawe OD, Carter DK, Hural J, Akondy R et al..  2008.  HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis.. Lancet. 372(9653):1894-905. Abstract
2010
Asmuth DM, Brown EL, DiNubile MJ, Sun X, del Rio C, Harro C, Keefer MC, Kublin JG, Dubey SA, Kierstead LS et al..  2010.  Comparative cell-mediated immunogenicity of DNA/DNA, DNA/adenovirus type 5 (Ad5), or Ad5/Ad5 HIV-1 clade B gag vaccine prime-boost regimens.. The Journal of infectious diseases. 201(1):132-41. Abstract
2011
Fellay J, Frahm N, Shianna KV, Cirulli ET, Casimiro DR, Robertson MN, Haynes BF, Geraghty DE, McElrath MJ, Goldstein DB.  2011.  Host genetic determinants of T cell responses to the MRKAd5 HIV-1 gag/pol/nef vaccine in the step trial.. The Journal of infectious diseases. 203(6):773-9. Abstract
Rolland M, Tovanabutra S, Decamp AC, Frahm N, Gilbert PB, Sanders-Buell E, Heath L, Magaret CA, Bose M, Bradfield A et al..  2011.  Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial.. Nature medicine. 17(3):366-71. Abstract
Nicholson O, Dicandilo F, Kublin J, Sun X, Quirk E, Miller M, Gray G, Pape J, Robertson MN, Mehrotra DV et al..  2011.  Safety and Immunogenicity of the MRKAd5 gag HIV Type 1 Vaccine in a Worldwide Phase 1 Study of Healthy Adults.. AIDS research and human retroviruses. 27(5):557-567. Abstract
2012
Qureshi H, Ma Z-M, Huang Y, Hodge G, Thomas MA, Dipasquale J, Desilva V, Fritts L, Bett AJ, Casimiro DR et al..  2012.  Low-Dose Penile SIVmac251 Exposure of Rhesus Macaques Infected with Adenovirus Type 5 (Ad5) and Then Immunized with a Replication-Defective Ad5-Based SIV gag/pol/nef Vaccine Recapitulates the Results of the Phase IIb Step Trial of a Similar HIV-1 Vaccine.. Journal of virology. 86(4):2239-50. Abstract
Frahm N, Decamp AC, Friedrich DP, Carter DK, Defawe OD, Kublin JG, Casimiro DR, Duerr A, Robertson MN, Buchbinder SP et al..  2012.  Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine.. The Journal of clinical investigation. 122(1):359-67. Abstract
Koblin BA, Mayer KH, Noonan E, Wang C-Y, Marmor M, Sanchez J, Brown SJ, Robertson MN, Buchbinder SP.  2012.  Sexual risk behaviors, circumcision status and pre-existing immunity to adenovirus type 5 among men who have sex with men participating in a randomized HIV-1 vaccine efficacy trial: Step Study.. Journal of acquired immune deficiency syndromes (1999). Abstract
Duerr A, Huang Y, Buchbinder S, Coombs RW, Sanchez J, del Rio C, Casapia M, Santiago S, Gilbert P, Corey L et al..  2012.  Extended Follow-up Confirms Early Vaccine-Enhanced Risk of HIV Acquisition and Demonstrates Waning Effect Over Time Among Participants in a Randomized Trial of Recombinant Adenovirus HIV Vaccine (Step Study).. The Journal of infectious diseases. 206(2):258-266. Abstract
2013
Duerr A, Huang Y, Buchbinder S, Coombs RW, Sanchez J, del Rio C, Casapia M, Santiago S, Huang Y, Gilbert P et al..  2013.  Reply to richie and villasante.. The Journal of infectious diseases. 207(4):690-2.
Hertz T, Ahmed H, Friedrich DP, Casimiro DR, Self SG, Corey L, McElrath MJ, Buchbinder S, Horton H, Frahm N et al..  2013.  HIV-1 vaccine-induced T-cell responses cluster in epitope hotspots that differ from those induced in natural infection with HIV-1.. PLoS pathogens. 9(6):e1003404. Abstract
Adenoviridae
Asmuth DM, Brown EL, DiNubile MJ, Sun X, del Rio C, Harro C, Keefer MC, Kublin JG, Dubey SA, Kierstead LS et al..  2010.  Comparative cell-mediated immunogenicity of DNA/DNA, DNA/adenovirus type 5 (Ad5), or Ad5/Ad5 HIV-1 clade B gag vaccine prime-boost regimens.. The Journal of infectious diseases. 201(1):132-41. Abstract
Priddy FH, Brown D, Kublin J, Monahan K, Wright DP, Lalezari J, Santiago S, Marmor M, Lally M, Novak RM et al..  2008.  Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults.. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 46(11):1769-81. Abstract
Adenoviruses, Human
Qureshi H, Ma Z-M, Huang Y, Hodge G, Thomas MA, Dipasquale J, Desilva V, Fritts L, Bett AJ, Casimiro DR et al..  2012.  Low-Dose Penile SIVmac251 Exposure of Rhesus Macaques Infected with Adenovirus Type 5 (Ad5) and Then Immunized with a Replication-Defective Ad5-Based SIV gag/pol/nef Vaccine Recapitulates the Results of the Phase IIb Step Trial of a Similar HIV-1 Vaccine.. Journal of virology. 86(4):2239-50. Abstract
Adjuvants, Immunologic
Asmuth DM, Brown EL, DiNubile MJ, Sun X, del Rio C, Harro C, Keefer MC, Kublin JG, Dubey SA, Kierstead LS et al..  2010.  Comparative cell-mediated immunogenicity of DNA/DNA, DNA/adenovirus type 5 (Ad5), or Ad5/Ad5 HIV-1 clade B gag vaccine prime-boost regimens.. The Journal of infectious diseases. 201(1):132-41. Abstract
Adolescent
Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, Gilbert PB, Lama JR, Marmor M, del Rio C et al..  2008.  Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial.. Lancet. 372(9653):1881-93. Abstract
Adult
Priddy FH, Brown D, Kublin J, Monahan K, Wright DP, Lalezari J, Santiago S, Marmor M, Lally M, Novak RM et al..  2008.  Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults.. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 46(11):1769-81. Abstract
Fellay J, Frahm N, Shianna KV, Cirulli ET, Casimiro DR, Robertson MN, Haynes BF, Geraghty DE, McElrath MJ, Goldstein DB.  2011.  Host genetic determinants of T cell responses to the MRKAd5 HIV-1 gag/pol/nef vaccine in the step trial.. The Journal of infectious diseases. 203(6):773-9. Abstract
Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, Gilbert PB, Lama JR, Marmor M, del Rio C et al..  2008.  Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial.. Lancet. 372(9653):1881-93. Abstract
Asmuth DM, Brown EL, DiNubile MJ, Sun X, del Rio C, Harro C, Keefer MC, Kublin JG, Dubey SA, Kierstead LS et al..  2010.  Comparative cell-mediated immunogenicity of DNA/DNA, DNA/adenovirus type 5 (Ad5), or Ad5/Ad5 HIV-1 clade B gag vaccine prime-boost regimens.. The Journal of infectious diseases. 201(1):132-41. Abstract
AIDS Vaccines
Rolland M, Tovanabutra S, Decamp AC, Frahm N, Gilbert PB, Sanders-Buell E, Heath L, Magaret CA, Bose M, Bradfield A et al..  2011.  Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial.. Nature medicine. 17(3):366-71. Abstract
Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, Gilbert PB, Lama JR, Marmor M, del Rio C et al..  2008.  Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial.. Lancet. 372(9653):1881-93. Abstract
Qureshi H, Ma Z-M, Huang Y, Hodge G, Thomas MA, Dipasquale J, Desilva V, Fritts L, Bett AJ, Casimiro DR et al..  2012.  Low-Dose Penile SIVmac251 Exposure of Rhesus Macaques Infected with Adenovirus Type 5 (Ad5) and Then Immunized with a Replication-Defective Ad5-Based SIV gag/pol/nef Vaccine Recapitulates the Results of the Phase IIb Step Trial of a Similar HIV-1 Vaccine.. Journal of virology. 86(4):2239-50. Abstract